Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds?
Key takeaways
- Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds?
- Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
- Bristol-Myers Squibb Company (NYSE:BMY) announced on May 20 that it was partnering with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions.
Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds? Sultan Khalid Mon, May 25, 2026 at 12:25 AM GMT+7 2 min read BMY ANTH.PVT With an annual dividend yield of 4.25%, Bristol-Myers Squibb Company (NYSE:BMY) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds.
Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Bristol-Myers Squibb Company (NYSE:BMY) announced on May 20 that it was partnering with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions. The agreement will provide over 30,000 BMS employees with the platform and signals a significant evolution in how the pharma company deploys AI, extending well beyond the general-purpose chat tools and toward “agentic capabilities built into the day-to-day workflows and systems that underpin its science and global operations”.